Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician, Eur J Nucl Med Mol Imaging, vol.44, pp.41-54, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01856113
Targeting the PD1/ PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities, Crit Rev Oncol Hematol, vol.89, pp.140-65, 2014. ,
Cancer immunotherapy comes of age, Nature, vol.480, pp.480-489, 2011. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-64, 2012. ,
The PD1:PD-L1/2 pathway from discovery to clinical implementation, Front Immunol, vol.7, p.550, 2016. ,
CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, vol.39, pp.98-106, 2016. ,
Toward precision radiotherapy for use with immune checkpoint blockers, Clin Cancer Res, vol.24, pp.259-65, 2018. ,
Molecular pathways: immune checkpoint antibodies and their toxicities, Clin Cancer Res, vol.22, pp.4550-4555, 2016. ,
Tumourand class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review, Ann Oncol, vol.28, pp.2377-85, 2017. ,
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience, Invest New Drugs, vol.36, pp.638-684, 2018. ,
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management, ESMO Open, vol.3, 2018. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009. ,
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti ,
, Clin Cancer Res, vol.23, pp.1920-1928, 2017.
Hyperprogression during anti-PD-1/ PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.28, pp.1605-1616, 2017. ,
Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, vol.375, pp.1856-67, 2016. ,
Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab, J Clin Oncol, vol.34, pp.1510-1517, 2016. ,
Can an immune checkpoint inhibitor (sometimes) make things worse?, Clin Cancer Res, vol.23, pp.1879-81, 2017. ,
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-52, 2017. ,
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, vol.35, pp.1773-82, 1999. ,
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study, Eur J Nucl Med Mol Imaging, vol.42, pp.386-96, 2015. ,
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, issue.1, pp.122-50, 2009. ,
Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC, Eur J Nucl Med Mol Imaging, vol.45, pp.56-66, 2018. ,
Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma, J Nucl Med, vol.58, pp.1421-1429, 2017. ,
Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab, Eur J Nucl Med Mol Imaging, vol.45, pp.376-83, 2018. ,
The role of interim (18)F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma, Eur J Nucl Med Mol Imaging, vol.45, pp.1289-96, 2018. ,
Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy, Pigment Cell Melanoma Res, vol.29, pp.572-579, 2016. ,
Dynamic adaptation of tumor immune response with nivolumab demonstrated by 18F-FDG PET/CT, Clin Nucl Med, vol.43, pp.114-120, 2018. ,
Is it time to change our vision of tumor metabolism prior to immunotherapy?, Eur J Nucl Med Mol Imaging, vol.45, pp.1072-1077, 2018. ,
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer, World J Surg Oncol, vol.14, p.238, 2016. ,
FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with non-small-cell lung cancer, J Thorac Oncol, 2018. ,
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery, Eur J Nucl Med Mol Imaging, vol.43, pp.1954-61, 2016. ,
Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography, Cancer Med, vol.6, pp.2552-61, 2017. ,
Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer, J Surg Res, vol.171, pp.1-5, 2011. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014. ,
Low PD-1 expression in cytotoxic CD8(+) tumorinfiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value, Clin Cancer Res, vol.24, pp.407-426, 2018. ,
Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab, EJNMMI Res, vol.6, p.61, 2016. ,
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors, Eur J Nucl Med Mol Imaging, vol.44, pp.2310-2335, 2017. ,
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade, J Immunother Cancer, vol.4, p.58, 2016. ,
Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT ,
, Acad Radiol, vol.24, pp.111-116, 2017.
Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol, vol.2, pp.1346-53, 2016. ,
Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer, JAMA Oncol, vol.4, pp.374-382, 2018. ,
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis, Eur J Nucl Med Mol Imaging, vol.40, pp.133-173, 2013. ,
Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs), EJNMMI Res, vol.7, p.30, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01856125
18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer, Eur J Nucl Med Mol Imaging, vol.43, pp.2324-2359, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01386846
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies, Eur J Nucl Med Mol Imaging, vol.44, pp.17-31, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01856095